Author: Bein, Thomas; Grasso, Salvatore; Moerer, Onnen; Quintel, Michael; Guerin, Claude; Deja, Maria; Brondani, Anita; Mehta, Sangeeta
Title: The standard of care of patients with ARDS: ventilatory settings and rescue therapies for refractory hypoxemia Document date: 2016_4_4
ID: krpg9u1u_45
Snippet: Despite significant improvements in oxygenation, inhaled nitric oxide (iNO) does not reduce mortality in patients with ARDS regardless of the severity of hypoxemia, and it may increase the risk of renal impairment [80] . A recent meta-analysis which included nine randomized trials (n = 1142 patients) with no between-trial heterogeneity (I = 0 %) showed that iNO did not reduce mortality in patients with severe ARDS (risk ratio 1.01; 95 % CI 0.78-1.....
Document: Despite significant improvements in oxygenation, inhaled nitric oxide (iNO) does not reduce mortality in patients with ARDS regardless of the severity of hypoxemia, and it may increase the risk of renal impairment [80] . A recent meta-analysis which included nine randomized trials (n = 1142 patients) with no between-trial heterogeneity (I = 0 %) showed that iNO did not reduce mortality in patients with severe ARDS (risk ratio 1.01; 95 % CI 0.78-1.32) nor in mild-moderate ARDS (risk ratio 1.12; 95 % CI 0.89-1.42) [81] . Moreover, analysis of PaO 2 /FiO 2 ratio subgroups ranging from 70 to 200 mmHg did not identify a threshold for which iNO reduces mortality [80] . The effectiveness, safety, and cost of inhaled epoprostenol (iEPO) versus iNO was addressed by a retrospective single-center study of 105 patients [82] , but there were no between-group differences in several clinical and outcome parameters.
Search related documents:
Co phrase search for related documents- oxygenation significant improvement and significant improvement: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22
- randomized trial and renal impairment: 1, 2, 3, 4, 5
- randomized trial and risk ratio: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70
- randomized trial and significant improvement: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72
- randomized trial and single center: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72
- randomized trial and single center study: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35
- randomized trial and trial heterogeneity: 1
- renal impairment and significant improvement: 1
- renal impairment and single center: 1, 2
- renal impairment and single center study: 1, 2
- risk ratio and significant improvement: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16
- risk ratio and single center: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32
- risk ratio and single center study: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16
- risk ratio and trial heterogeneity: 1, 2, 3
- severe ARDS patient and significant improvement: 1, 2
- severe ARDS patient and single center: 1
- severe ARDS patient and single center study: 1
- significant improvement and single center: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28
- significant improvement and single center study: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
Co phrase search for related documents, hyperlinks ordered by date